ES2171018T3 - Uso de agentes inmunomoduladores. - Google Patents

Uso de agentes inmunomoduladores.

Info

Publication number
ES2171018T3
ES2171018T3 ES98917808T ES98917808T ES2171018T3 ES 2171018 T3 ES2171018 T3 ES 2171018T3 ES 98917808 T ES98917808 T ES 98917808T ES 98917808 T ES98917808 T ES 98917808T ES 2171018 T3 ES2171018 T3 ES 2171018T3
Authority
ES
Spain
Prior art keywords
immunomodulating agents
pka
well
pharmaceutical compositions
protein kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98917808T
Other languages
English (en)
Inventor
Kjetil Tasken
Einar Martin Aandahl
Pael Aukrust
Bjorn S Skalhegg
Fredrik Muller
Stig Froeland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lauras AS
Original Assignee
Lauras AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lauras AS filed Critical Lauras AS
Application granted granted Critical
Publication of ES2171018T3 publication Critical patent/ES2171018T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)

Abstract

El uso de inhibidores seleccionados del grupo que consiste en antagonistas de cAMP, ribozimas de cabeza de martillo, oligonucleótidos antisentido específicos de secuencia y péptidos de ruptura de anclaje, en el que dichos inhibidores suprimen la función de la proteína-quinasa (PKA) de tipo I(RI2C2) dependiente de cAMP, para producir una preparación farmacéutica para tratar enfermedades inmunosupresoras.
ES98917808T 1997-04-29 1998-04-29 Uso de agentes inmunomoduladores. Expired - Lifetime ES2171018T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO971997A NO971997D0 (no) 1997-04-29 1997-04-29 Bruk av immunmodulerende midler

Publications (1)

Publication Number Publication Date
ES2171018T3 true ES2171018T3 (es) 2002-08-16

Family

ID=19900676

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98917808T Expired - Lifetime ES2171018T3 (es) 1997-04-29 1998-04-29 Uso de agentes inmunomoduladores.

Country Status (13)

Country Link
US (1) US20050250727A1 (es)
EP (1) EP1024809B1 (es)
JP (2) JP2002501499A (es)
AT (1) ATE213944T1 (es)
AU (1) AU738674B2 (es)
CA (1) CA2288215C (es)
DE (1) DE69804125T2 (es)
DK (1) DK1024809T3 (es)
ES (1) ES2171018T3 (es)
NO (1) NO971997D0 (es)
NZ (1) NZ501181A (es)
PT (1) PT1024809E (es)
WO (1) WO1998048809A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080186A2 (en) * 1998-05-27 2001-03-07 Lauras AS Method for altering the activity of proteins of the pka signaling pathway
NZ513642A (en) * 1999-01-21 2004-02-27 Metamorphix Inc Growth differentiation factor inhibitors and uses therefor
WO2001042470A1 (en) * 1999-12-07 2001-06-14 University Of Medicine And Dentistry Of New Jersey Nucleic acid and protein expressed thereby and their involvement in stress
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
WO2005060996A2 (en) * 2003-12-23 2005-07-07 Lauras As Method of altering the pka type i signalling pathway
GB0413726D0 (en) 2004-06-18 2004-07-21 Lauras As Compounds
GB0421355D0 (en) * 2004-09-24 2004-10-27 Univ Oslo Inhibitors
GB0518027D0 (en) * 2005-09-05 2005-10-12 Birkeland Innovasjon As Compounds
GB0618235D0 (en) * 2006-09-15 2006-10-25 Lauras As Process
CA2914615C (en) 2013-06-05 2023-10-17 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CN108779435B (zh) 2015-12-07 2022-05-03 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
US20230285556A1 (en) * 2021-09-13 2023-09-14 Omeros Corporation Methods and compositions for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
US5276017A (en) * 1990-09-14 1994-01-04 Trustees Of The University Of Pennsylvania Therapeutic and diagnostic applications of tropho-uteronectin (TUN) manipulation
US6429208B1 (en) * 1992-03-27 2002-08-06 Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
WO1993021929A1 (en) * 1992-05-01 1993-11-11 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Phosphorothioate derivatives of cyclic amp analogues
EP0681482B1 (en) * 1993-01-22 2005-12-07 University Research Corporation Localization of therapeutic agents
US5807693A (en) * 1994-11-23 1998-09-15 Icos Corporation Calcineurin inhibitory compounds and anchoring protein
US5795735A (en) * 1995-07-17 1998-08-18 Icos Corporation Isolated polynucleotides encoding PKA-binding proteins and methods of producing the proteins recombinantly
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide

Also Published As

Publication number Publication date
NZ501181A (en) 2002-03-01
EP1024809B1 (en) 2002-03-06
ATE213944T1 (de) 2002-03-15
AU7086598A (en) 1998-11-24
DK1024809T3 (da) 2002-06-24
JP2002501499A (ja) 2002-01-15
NO971997D0 (no) 1997-04-29
JP2010111688A (ja) 2010-05-20
CA2288215A1 (en) 1998-11-05
CA2288215C (en) 2009-08-18
DE69804125T2 (de) 2002-10-31
EP1024809A1 (en) 2000-08-09
PT1024809E (pt) 2002-07-31
DE69804125D1 (de) 2002-04-11
AU738674B2 (en) 2001-09-20
WO1998048809A1 (en) 1998-11-05
US20050250727A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
CA2137203A1 (en) Protein kinase c inhibitors
BR9810829B1 (pt) composto heterocìclico, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica.
DK0807111T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstillingen heraf samt farmaceutiske sammensætninger indeholdende disse
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
EA199900373A2 (ru) Фармацевтические композиции
CA2216535A1 (en) Protein kinase c inhibitors
HUP0103617A2 (hu) Protein kinázt gátló, pirrolilcsoporttal helyettesített 2-indolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
DK0912559T3 (da) Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
IL125735A (en) Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound
EA200200571A1 (ru) Новая композиция и ее применение
BR9807814B1 (pt) composto de pirazina, composiÇço farmacÊutica, uso de um composto, e, processo para a preparaÇço de um composto.
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
NO971137L (no) Dimetyl-(3-aryl-but-3-enyl)-aminforbindelse som farmasöytiske forbindelser
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
NO971997D0 (no) Bruk av immunmodulerende midler
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
NO991563L (no) N-substituerte, azaheterosykliske forbindelser
TR200000152T2 (tr) Yeni bileşikler.
NO984290L (no) Farmas°ytisk nyttige forbindelser
PL338004A1 (en) Derivatives of azetidinylpropylpiperidine, intermediate compounds and application of such derivatives as antagonists of tachykinins
BR9711311B1 (pt) derivado de 1,2,3,4-tetrahidroquinolina, composiÇço farmaceutica, uso de um derivado de 1,2,3,4-tetrahidroquinolina, e, processo para a preparaÇço de compostos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1024809

Country of ref document: ES